Loading stock data…
Taysha Gene Therapies (TSHA)
$5.54-0.06 (-1.07%)
Market OpenUpdated 3:21 PM EDT
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Taysha Gene Therapies, Inc. in the Healthcare sector is trading at $5.54 with a market capitalization of $1.6B. Wall Street consensus targets $13.33 (12 analysts), implying a +140.7% move over the next 12 months. The stock is currently 24% below its 52-week high of $7.30, remaining 1.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +140.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 31) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $5.49M | $0↓ | $1.99M↓ | $2.30M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$43.49M↓ | -$28.30M↑ | -$34.02M↓ | -$26.75M↓ | -$21.42M |
| Net Income | -$42.41M↓ | -$27.85M↑ | -$32.73M↓ | -$26.88M↓ | -$21.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company prima...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.62B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-61.28%
Volume
Today's trading volume
896,569
Recent News
These 3 Risky Stocks Could Be Sitting on 100% Upside
Analysts see high-risk, high-reward potential in Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources, each projected to roughly double despite significant company-specific risks.
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
TSHA-102 dosing complete in pivotal Rett syndrome trials with 100% responder rate.
Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger
Taysha Gene Therapies (TSHA) drew fresh investor attention after reporting a 100% overall response rate in early TSHA-102 Rett syndrome trial data, expanding its Catalent manufacturing agreement, and outlining cash coverage into late 2028. See our latest analysis for Taysha Gene Therapies. Taysha Gene Therapies has seen its share price move around these updates, with a 19.05% 30 day share price return and a very large 1 year total shareholder return, while the 5 year total shareholder return...
Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary
Moby summary of Taysha Gene Therapies, Inc.'s Q2 2026 earnings call
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...
Company reports 100% response rate in Part A trial, completes pivotal dosing, and maintains $455.4 million cash position into 2028